<DOC>
	<DOCNO>NCT00587054</DOCNO>
	<brief_summary>This phase II , single-center study evaluate efficacy novel cytoreductive regimen follow CD34+E- select T cell deplete allogeneic stem cell ( soybean agglutinate E-rosetted BM ) transplant treatment patient acute chronic leukemia , lymphoma myelodysplstic syndrome/PNH . The impact change condition regimen use CD34-selected T cell deplete PBSCs transplant related morbidity mortality disease free survival assess .</brief_summary>
	<brief_title>Trial Allogeneic Stem Cell Transplants From HLA Compatible , Related Unrelated Donors After Myeloablative Preparative Regimen With Hyperfractionated TBI , Thiotepa Fludarabine For Adult Patients With Lymphohematopoietic Disorders</brief_title>
	<detailed_description>The purpose study : ( 1 ) try kill cancer precancer cell body , reduce side effect transplant , see previous study , ( 2 ) see treatment new recipe radiation chemotherapy suppress immune system enough stem cell 'take ' grow , ( 3 ) see specially prepared stem cell grow without problem call graft-versus-host disease ( GvHD ) occur . One major side effect stem cell transplant condition know graft vs. host disease GVHD . GVHD immune reaction cause certain cell transplant stem cell call T-lymphocytes ( T-cells ) . The T-cells donor may see organ foreign attack . New way remove T-cells stem cell transplant use try prevent GVHD . In study , removal T-cells stem cell successful many patient prevent short-term ( acute ) long-term ( chronic ) form GVHD . However , removal T-cells may increase chance new bone marrow develop stem cell reject function well . Rejection transplant mean cell survive chemo radiation therapy , attack new bone marrow cell . This condition lifethreatening increase risk infection bleed would require get treatment additional stem cell . Studies like one design find good way avoid GVHD without increase risk problem graft rejection .</detailed_description>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<criteria>Histologically proven acute chronic leukemia , non Hodgkins lymphoblastic lymphoma myelodysplastic syndrome HLA 6/6 5/6 antigen match related unrelated donor creatinine = normal , CrCl &gt; 60 ml/min/1.73ml total bilirubin &lt; 2.5 , AST &lt; 2xnl , cardiac function &gt; 50 % pulmonary function asymptomatic DLCO &gt; % 50 % ( correct Hgb ) Karnofsky performance status &gt; 70 % negative pregnancy test ( applicable ) sign informed consent patient donor . Pregnancy lactation unwillingness comply protocol treatment followup uncontrolled infection HIV HTLV positivity active CNS/skin disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>leukemia</keyword>
	<keyword>non-Hodgkins</keyword>
	<keyword>lymphoblastic lymphoma</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>paroxysmal nocturnal hemoglobinuria ( PNH )</keyword>
	<keyword>cytoreductive regimen</keyword>
	<keyword>allogeneic stem cell transplant</keyword>
</DOC>